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suppliers of commercial services, or commercial supporters.
Planners have reviewed content to ensure there is no bias. 
This presentation will not include any discussion of the 
unlabeled use of a product or products under investigational 
use.
Objectives
At the conclusion of this session, the participant 
will be able to:
 Review the geographic distribution of Lyme disease, Southern tick-
associated rash illness (STARI), Rocky Mountain spotted fever, 
ehrlichiosis, anaplasmosis, and other emerging tickborne diseases.
 Define the symptoms of Lyme disease, STARI, Rocky Mountain spotted 
fever, ehrlichiosis, anaplasmosis, and emerging tickborne diseases.
 Identify the serologic tests used to diagnose Lyme disease, Rocky 
Mountain spotted fever, ehrlichiosis, anaplasmosis, and emerging 
tickborne diseases.
 Describe the appropriate use of antibiotics in treating Lyme disease, 
STARI, Rocky Mountain spotted fever, ehrlichiosis, anaplasmosis, and 
emerging tickborne diseases.
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Leading Tickborne Diseases in the U.S.
 Lyme disease (Borrelia burgdorferi)
 Rocky Mountain spotted fever (Rickettsia rickettsii)
 Ehrlichiosis (Ehrlichia chaffeensis, others) 
 Anaplasmosis (Anaplasma phagocytophilum)
 Babesiosis (Babesia microti)
For information on other tickborne diseases, visit www.cdc.gov/ticks
Selected Tick Vectors










Rocky Mtn. Spotted Fever
Tularemia
Distribution of Key Tickborne Diseases, 2014
Diseases are 
reported to CDC 
by county of 
residence. Each 
dot represents 
one case. The 
county where the 
disease was 
diagnosed is not 
necessarily the 
county where the 
disease was 
acquired.
* L A B * 
Lyme Disease
 Caused by spirochete Borrelia 
burgdorferi  (and newly discovered 
Borrelia mayonii)
 Occurs in areas of North America, 
Europe, and Asia
 ~30,000 cases reported annually in US
 Transmitted in US by blacklegged ticks
Diseases reported to CDC by county of residence. Each dot represents one case. The county 
where the disease was diagnosed is not necessarily the county where the disease was acquired.
Reported Lyme Disease Cases, 2014
Erythema Migrans (EM)
• 70-80% of cases
• ~7-14 days after tick bite
• Expands over days
• Rarely painful
• Distinguish from allergic 
reaction
Atypical EM Presentations
Nadelman RB, Wormser GP. Management of tick bites and early Lyme disease. Rahn DW, 
Evans J eds. Lyme disease. 1998; Philadelphia: American College of Physicians. 49-75.
Disseminated and Late Lyme Disease
 Facial palsy 
 Summer months







Two-tiered testing for Lyme disease
Sensitivity of Two-Tiered Serologic Testing
Lyme Disease Stage Sensitivity (%)
EM rash (acute) 38




Bacon et al. JID 2003; 187:1187–99
Bottom line:
 Good in later stages of disease
 Testing of patients with EM and exposure in an endemic area is 
not generally necessary
Specificity of two-tiered testing is generally > 95% 
Additional Tests:  Questionable Utility
 Single-tier Western blot tests without a previous EIA
 In-house criteria for interpretation of Western blots 
 Capture assays for antigens in urine 
 Tests for “cystic forms” of B. burgdorferi
 Lymphocyte transformation tests 
 Quantitative CD57 lymphocyte assays 
 Novel culture techniques
More info on www.cdc.gov/Lyme
Concerns regarding new culture method for Borrelia burgdorferi not approved for the diagnosis of Lyme disease
Prognosis
 Most patients treated with antibiotics recover completely
 In patients with persistent or recurrent joint swelling, re-treatment 
with a second 4-week course may be needed 
 Some patients – particularly those diagnosed with later stages of 
disease – may have persistent symptoms of fatigue, muscle 
aches, reduced concentration   
- Preferred term for this is Post-treatment Lyme Disease Syndrome 
(PTLDS)
- Placebo-controlled trials have not shown a sustained benefit of extended 
antibiotic treatment
Prevention – Talk About It!
 Avoid tick habitat
 Use DEET and wear permethrin-treated clothing
 After being outdoors:
 Tumble clothes in the dryer on high heat for 5-10 min
 Shower within 2 hrs – washes away unseen nymphs 
 Daily tick checks – remove attached ticks ASAP
 Treat pets appropriately for ticks year-round
Nelson et al. The heat is on: Killing blacklegged ticks in residential washers and 
dryers to prevent tickborne diseases. Ticks Tick Borne Dis. 2016 Apr 28. 
Antibiotic prophylaxis 
for patients with a tick bite
Single dose of doxycycline for prevention of Lyme disease when all of the 
following conditions are met: 
 Highly endemic area
 Attached tick identified as an adult or nymphal I. scapularis
 Tick attached for > 36 hours based on engorgement or history
 Prophylaxis can be started within 72 hrs. of tick removal
 Doxycycline treatment is not contraindicated
Dose = 200 mg po x 1 for adults
From: The Clinical Assessment, Treatment and Prevention of Lyme disease, human granulocytic anaplasmosis 
and babesiosis: Clinical practice guidelines from the Infectious Diseases Society of America; CID; 2006
Emerging Tickborne Diseases
STARI
STARI or Lyme Disease?
 Southern tick-associated rash illness 
(STARI)
 Rash indistinguishable from Lyme 
disease EM
 May be accompanied by fatigue, 
fever, headache, muscle and joint 
pains
 Follows bite of lone star tick, 
Amblyomma americanum
 Also known as Master’s disease
 Cause of STARI is not known
Southern Tick-associated Rash Illness (STARI)
Life stages of lone star tick 
(Amblyomma americanum)
Treatment of STARI
 It is not known whether antibiotic treatment is 
necessary or beneficial for patients with STARI
 STARI has not been linked to arthritis, neurologic 
disease, or chronic symptoms
 Nevertheless, because STARI resembles early Lyme 
disease, physicians will often treat patients with oral 
antibiotics
Lantos et al. Empiric antibiotic treatment of EM-like skin lesions as a function of geography: a 
clinical and cost effectiveness modeling study. Vector Borne Zoonotic Dis 2013;13(12):877-83. 
 Relapsing fever spirochete
 Detected in I. scapularis ticks in CT in 2001
 First report of human infection in 2011 (Russia)
 First report of human infection in U.S. in 2013
 Until very recently, 4 cases reported
• All >60 years old and 2 immunocompromised
 Present in approximately 2% (up to 10.5%) of Ixodes spp. 
ticks in U.S.
Wormser and Pritt, 2015
Borrelia miyamotoi
Molloy et al. 2015
Borrelia miyamotoi
 Human blood samples from May 2013 – Oct 2014
 11,515 samples tested (B. miyamotoi DNA in 0.8%)
 97 patients positive by 2 PCR assays (genus, species)  Clinical data on 
51 patients
 Onset in July/August
 Most patients experienced fever (96%), headache (96%), myalgia (84%), 
malaise (82%), and arthralgia (76%)
 Hospitalized (24%); Immunocompromised – ?
Borrelia mayonii: An Emerging 
Tickborne Pathogen
Elizabeth Schiffman, MPH, MA
Vectorborne Disease Program 
Minnesota Department of Health
Lyme Disease
 Disease caused by bacteria in the Borrelia burgdorferi sensu 
lato (Bbsl) complex
 In United States, Borrelia burgdorferi sensu stricto
 In Europe, Borrelia afzelii, Borrelia garinii, and Borrelia 
burgdorferi
 The Bbsl complex does not include the relapsing fever group 
of Borrelia (e.g., B. hermsii, B. miyamotoi)
Lyme Disease Diagnosis
 Based on clinical presentation and a history of exposure to 
blacklegged ticks in an area where Lyme disease is endemic
 Serology 
 Two-tiered approach recommended, using FDA-
approved tests
 Not needed for early Lyme disease with single erythema 
migrans (EM) rash
 Important for disseminated infections or illness without 
EM rash
Lyme Disease PCR Test
 Commercial assays are available to test blood, CSF, synovial fluid, 
and tissue
 Considered an adjunct test rather than for routine diagnostics 
 Advantage of direct detection in acute illness – no need to wait 
for antibodies to develop 
 Major disadvantage is low sensitivity
 Blood is positive in only 50% of acute cases with EM 
 CSF is positive only 1/3 of patients with early neuroborreliosis 
Index Case – June 2013
 10-year-old male from northwestern Minnesota
 Presented with fever, headache, neck pain, myalgia, 
nausea/vomiting, and diffuse rash (not typical EM)
 Spent the week prior in Spooner, WI
 Patient was hospitalized for 4 days




PCR Melting Temperature Analysis
Additional Cases Identified
 PCR on whole blood positive
 11-year-old male from WI in July 2013
 Retrospective review also identified a 65-year-old male 
from ND (exposure in MN) from July 2012
 Synovial fluid specimen from Mayo Clinic Eau Claire 
 21-year-old woman from WI in June 2013
 Two additional cases in 2014
Sequence Analysis of Atypical oppA1 PCR 
Products
Dark Field Microscopy and Cultures
Source: Centers for Disease Control 
Phylogenetic Analysis 
 8 housekeeping genes: 
 uvrA, rplB, recG, pyrG, pepX, 
clpX, clpA, nifS
Multi-Locus Sequence Analysis (MLSA)
 8-gene MLSA performed
 Previously used for defining Bbsl genospecies
 Highest pairwise similarity was to B. burgdorferi (94.9 to 
95.2%)
 Threshold for separating genospecies = 98.3% similarity
 Results confirmed that this is a novel Bbsl genospecies
 Proposed name is Borrelia mayonii
Patient Samples Analyzed
Patients: MN, WI, ND
9,197 specimens
Patients: All states
Nov. 2003 – Sept. 2014
100,545 specimens
Patients: All states
Nov. 2003 – Dec. 2011
66,562 specimens
Patients: All states
Jan. 2012 – Sept. 2014
33,983 specimens
No B. mayonii 
positives
Patients: 44 states 
(not MN, WI, ND)
24,786 specimens
6 B. mayonii 
positives
No B. mayonii 
positives
Clinical Features of Patients (n=6)
 Ages ranged from 10 to 67 years; 4 male, 2 female
 2 patients had a known tick bite, but all reported exposure to 
ticks or tick habitat in Minnesota or Wisconsin
 5 presented with an acute febrile illness
 3 had potential neurologic involvement (confused speech, 
profound somnolence, visual difficulties)
 4 had rash – only 1 was suggestive of an EM
 1 had arthralgia
Patient Outcomes
 2 of 6 patients were hospitalized 
 All were treated with antibiotics recommended for 
treatment of Lyme disease
 5 patients recovered completely, while 1 reported residual 
joint pain
Patient Exposure and Residence Locations










Bb IgM Immunoblot Result 
(number of bands 
detected/possible bands)
Bb IgG Immunoblot Result 
(number of bands 
detected/possible bands)
1 6 N/A Positive Positive (2/3) Negative (1/10)
3 2 N/A Equivocal Negative (0/3) Negative (0/10)
3 29 N/A Positive Positive (3/3) Negative (2/10)
3 104 Positive Positive Negative (0/3) Negative (4/10)
4 266 Positive Positive Negative (1/3) Positive (5/10)
51 3 Negative Positive Negative (0/3) Negative (0/10)
5 32 Positive Positive Positive (2/3) Negative (2/10)
61 1 Negative Negative Negative (0/3) Negative (1/10)
1 Specimen source was plasma rather than serum.
Tick Collection
 Ixodes scapularis ticks collected 
 2 sites in Wisconsin (2009-2010, 2013-2014) 
 4 sites in Minnesota (2014-2015)
 PCR testing performed for both B. burgdorferi and B. mayonii 
Wisconsin ticks – Mayo Laboratories 
Minnesota ticks – Minnesota Department of Health Public 
Health Laboratory





Adults Nymphs Adults Nymphs
Minnesota I. scapularis ticks1 14/855 (1.6) 2/203 (1.0) 374/855 (43.7) 50/203 (24.6)
Wisconsin I. scapularis ticks2 15/465 (3.2) 4/193 (2.1) 162/465 (34.8) 33/193 (17.1)
1 Minnesota ticks tested were from 2014-2015.
2 Wisconsin ticks tested were from 2009-2010 and 2013-2014.
Unique Features of B. mayonii
 Disease only identified in patients from the upper Midwest 
 Not detected in nearly 25,000 blood samples from other parts 
of the US
 Based on initial findings, seems to cause more severe disease 
than B. burgdorferi
 Rashes more diffuse than classic EM presentation
 Organism found primarily in whole blood
 Historically, <0.1% of blood positive for B. burgdorferi
Summary
 Still much to learn about this newly identified species of Borrelia –
unclear how common Lyme disease associated with B. mayonii really
is, but research indicates it recently emerged
 Both Minnesota and Wisconsin are considered high-incidence states 
for Lyme disease, and have several endemic tickborne diseases
 Risk for tickborne diseases is highly seasonal – late spring through 
mid-summer is period of highest risk
 Tickborne diseases, including B. mayonii, should be considered in 
patients presenting with febrile illness after outdoor exposures in the 
upper Midwest 
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 Nonspecific early clinical signs make them difficult to 
diagnose
 Some are rapidly progressing and may be fatal
 Increasing incidence
But…
 Are all treated with doxycycline
 Use similar laboratory methods for diagnostic 
confirmation 
Rickettsia rickettsii: 
Rocky Mountain spotted fever
 Gram-negative intracellular bacterium, 
endothelial cells
 Transmitted by Dermacentor variabilis, 
Dermacentor andersoni, and in some 
areas Rhipicephalus sanguineus
 Causes widespread vasculitis and multi-
system organ failure
 Rapidly fatal, yet difficult to  diagnose in 
early stage of illness (>20% case fatality 
rate in untreated cases)
Incidence of Spotted Fever Rickettsiosis, 2000-
2013
NOTE:  Incidence based on national surveillance data 2000-2013.  Surveillance reporting 
category changed to spotted fever rickettsiosis (including RMSF) in 2010.
RMSF: Early Clinical Manifestations 
(Days 1-4)
• Day 1-2: Fever, headache, myalgia (may be 
responsive to pain/fever meds)
• Day 2-4: May develop respiratory signs (cough) 
and/or gastrointestinal signs (nausea, vomiting, 
abdominal pain)
• Day 2-4: Faint maculopapular rash (variable)
 Small (1-5 mm), blanching, pink macules, 2 to 4 days 
after onset of fever
 First appears on wrists, ankles, forearms, spreads 
centrally
Initial Rash of RMSF
RMSF: Late Clinical Manifestations 
(Day 5 or Later)
• Worsening systemic illness (cough, dyspnea, 
arrhythmias, hypotension,  severe abdominal pain)
• Petechial rash may develop
• Thrombocytopenia, hyponatremia, elevated liver 
enzymes (AST, ALT) usually present
• Onset of neurologic signs (photophobia, altered 
mental status, seizures)
• Death
Petechiae on palms or soles typically do not 






Pulmonary edema Photos courtesy of Dr. Chris Paddock and Dr. Gerardo Alvarez Hernandez
Severe, late-stage manifestations of RMSF
Risk Factors for Fatal Outcome
 Delayed onset or absence of rash
 Age <10 years or ≥60 years
 Chronic conditions with signs/symptoms that overlap with RMSF 
(i.e. alcoholism, chronic lung disease)
 Glucose-6-phosphate dehydrogenase deficiency
 Off-season onset (colder months, first and last cases of the year)
 Delay in administration of effective therapy (doxycycline)
Other Pathogenic Tickborne Spotted Fever 
Rickettsioses
 Rickettsia parkeri rickettsiosis: 
 Transmitted by A. maculatum
 Southeastern United States
 Eschar-associated, febrile illness, no fatal cases
 Rickettsia species 364D rickettsiosis:
 Transmitted by D. occidentalis
 All cases have been reported out of California
 Eschar-associated, febrile illness, no fatal cases
 Rash not reported in few described cases
Paddock C, Goddard J, 2015. The evolving medical and veterinary importance of the Gulf Coast tick (Acari: Ixodidae). J Med Ent: tju022.
Ehrlichiosis
 Most commonly caused by Ehrlichia 
chaffeensis in United States
 Obligate intracellular bacteria which infect 
the peripheral blood leukocytes
Incidence of Ehrlichia chaffeensis, 2000-2013
NOTE: Incidence based on national surveillance data, 2000-2013
Symptoms—Ehrlichiosis
 Fever / chills
 Headache / malaise
 Muscle pain 
 Nausea / vomiting / diarrhea 
 Confusion 
 Rash 
• In up to 60% of children, less than 
30% of adults
 Thrombocytopenia, leukopenia and 
elevated liver enzymes
Severe clinical presentation 
may include multiple organ 




 Primarily reported out of Missouri, Arkansas
Indiana
 51 cases between 2008-2012
 Transmitted by A. americanum
 Ehrlichia muris eauclairensis
 First case confirmed in 2011
 38 cases to date
 Suspected transmission by I. scapularis
 Wisconsin and Minnesota
Anaplasmosis
 Caused by Anaplasma phagocytophilum
 Obligate intracellular bacteria which infect the peripheral blood 
leukocytes (predilection for granulocytes)
Incidence of Anaplasmosis, 2000-2013
NOTE: Incidence based on national surveillance data, 2000-
2013
Symptoms—Anaplasmosis
 Fever / chills
 Headache/ malaise
 Muscle pain 
 Thrombocytopenia, leukopenia, 
elevated liver enzymes and mild 
anemia
 Gastrointestinal symptoms







renal failure or 
toxic-shock-like 
syndrome.
Treating Rickettsioses—A Race Against Time
 Doxycycline is most effective treatment 
of RMSF and other rickettsial 
diseases in patients of all ages
 Treatment should be initiated early in 
patients of all ages with suspected 
rickettsial disease, before diagnosis 
confirmed
 Rapid treatment can prevent death and 
disability
Doxycycline Tooth Staining Study
 Short term doxycycline use does not:
 Darken shade of teeth
 Cause visible staining of teeth
 Increase risk of enamel hypoplasia
 Doxycycline can be safely administered to children 
without fear of tooth staining at dose and duration 
recommended for rickettsial diseases
Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with 
doxycycline for suspected rocky mountain spotted Fever. The Journal of pediatrics 2015; 166(5): 
1246-51.
Confirming a Rickettsial Infection
 Treatment decisions must be made by clinical suspicion 
 Do not base treatment decisions on (or wait for) 
confirmatory test results 
 Laboratory test selection will depend on level of disease 
progression, the suspected agent, and specimen 
availability
Testing Options
 PCR of whole blood, skin, or tissue
 Sensitive for ehrlichiosis and anaplasmosis during acute illness
 Generally insensitive for RMSF during acute illness until  late in disease 
progression
 Eschar swabs or biopsy sensitive specimens for detection of R. parkeri
and R. species 364D 
 Serology (IFA)
 Requires both an acute and a convalescent sample to be interpretable
 May be difficult to interpret due to cross-reactivity and antibody 
persistence
 IHC of skin or tissue
 Microscopy for detection of morulae
 For ehrlichiosis and anaplasmosis only
 Early symptoms are non-specific but can progress rapidly
 Early treatment with doxycycline is the best way to prevent severe 
disease, disability, and death
 Do not wait on confirmatory diagnostic test results to make a 
treatment decision




Updated guidelines on 
treatment, diagnosis and 





To Ask a Question
 Using the Webinar System
 “Click” the Q&A tab at the top left of the webinar tool bar
 “Click”  in the white space
 “Type” your question
 “Click” ask
 On the Phone
 Press Star (*) 1 to enter the queue
 State your name
 Listen for the operator to call your name 
 State your organization and then ask your question
Thank you for joining!
Please email us questions at coca@cdc.gov
Centers for Disease Control and Prevention 
Atlanta, Georgia
http://emergency.cdc.gov/coca 
Continuing Education  for COCA Calls
Continuing Education guidelines require that the attendance of all who 
participate in COCA Conference Calls be properly documented. All 
Continuing Education credits/contact hours (CME, CNE, CEU, CECH, 
ACPE and AAVSB/RACE) for COCA Conference Calls/Webinars are 
issued online through the CDC Training & Continuing Education Online 
system (http://www.cdc.gov/TCEOnline/).
Those who participate in the COCA Conference Calls and who wish to 
receive CE credit/contact hours and will complete the online evaluation by 
June 23, 2016 will use the course code WC2286. Those who wish to 
receive CE credits/contact hours and will complete the online evaluation 
between June 24, 2016 and May 24, 2017 will use course code WD2286. 
CE certificates can be printed immediately upon completion of your online 
evaluation. A cumulative transcript of all CDC/ATSDR CE’s obtained 
through the CDC Training & Continuing Education Online System will be 
maintained for each user. 
Join Us on 
Facebook
CDC Facebook page for 
clinicians! “Like” our page 
today to learn about 
upcoming COCA Calls, CDC 
guidance and 
recommendations, and 
about other health alerts
CDC Clinician Outreach and Communication Activity
https://www.facebook.com/CDCClinicianOutreachAndCommunicationActivity
